293 related articles for article (PubMed ID: 33859942)
1. Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers.
Kong Y; Ma Y; Zhao X; Pan J; Xu Z; Zhang L
Front Oncol; 2021; 11():638873. PubMed ID: 33859942
[TBL] [Abstract][Full Text] [Related]
2. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence.
Mireștean CC; Iancu RI; Iancu DT
Curr Oncol; 2022 Oct; 29(10):7388-7395. PubMed ID: 36290857
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies.
Yang W; Lei C; Song S; Jing W; Jin C; Gong S; Tian H; Guo T
Cancer Cell Int; 2021 Nov; 21(1):589. PubMed ID: 34727927
[TBL] [Abstract][Full Text] [Related]
7. The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy.
Wen L; Tong F; Zhang R; Chen L; Huang Y; Dong X
Front Oncol; 2021; 11():799957. PubMed ID: 34956911
[TBL] [Abstract][Full Text] [Related]
8. Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives.
Mortezaee K; Najafi M
Crit Rev Oncol Hematol; 2021 Jan; 157():103180. PubMed ID: 33264717
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed.
Huang W; Liu J; Xu K; Chen H; Bian C
Front Oncol; 2022; 12():849352. PubMed ID: 36313730
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review.
He H; Xu T; Li P; Jia G; Li X; Song Q
Front Oncol; 2021; 11():782646. PubMed ID: 34888252
[TBL] [Abstract][Full Text] [Related]
12. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review.
Wang NH; Lei Z; Yang HN; Tang Z; Yang MQ; Wang Y; Sui JD; Wu YZ
Ann Transl Med; 2022 Dec; 10(24):1406. PubMed ID: 36660640
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.
Deguchi T; Maekawa N; Konnai S; Owaki R; Hosoya K; Morishita K; Nakamura M; Okagawa T; Takeuchi H; Kim S; Kinoshita R; Tachibana Y; Yokokawa M; Takagi S; Kato Y; Suzuki Y; Murata S; Ohashi K
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37296981
[TBL] [Abstract][Full Text] [Related]
16. Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges.
Li Z; Sun G; Sun G; Cheng Y; Wu L; Wang Q; Lv C; Zhou Y; Xia Y; Tang W
Front Oncol; 2021; 11():771335. PubMed ID: 34869005
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.
Ostrand-Rosenberg S; Horn LA; Ciavattone NG
Front Oncol; 2019; 9():215. PubMed ID: 31001479
[TBL] [Abstract][Full Text] [Related]
18. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
